Concepts (121)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Malaria Vaccines | 7 | 2018 | 90 | 2.50 | Why? |
| Genetic Vectors | 6 | 2020 | 1600 | 1.32 | Why? |
| Malaria, Falciparum | 5 | 2018 | 377 | 1.16 | Why? |
| Antibodies, Protozoan | 5 | 2018 | 121 | 1.06 | Why? |
| Plasmodium falciparum | 5 | 2018 | 337 | 0.89 | Why? |
| Pan troglodytes | 1 | 2017 | 157 | 0.67 | Why? |
| Ebola Vaccines | 1 | 2017 | 126 | 0.61 | Why? |
| Clinical Trials, Phase II as Topic | 1 | 2017 | 801 | 0.52 | Why? |
| Immunization, Secondary | 6 | 2021 | 1649 | 0.50 | Why? |
| Cryopreservation | 1 | 2017 | 464 | 0.50 | Why? |
| T-Lymphocytes | 5 | 2020 | 6670 | 0.49 | Why? |
| Adenoviridae | 2 | 2017 | 1151 | 0.47 | Why? |
| Drug Carriers | 1 | 2017 | 590 | 0.45 | Why? |
| Interferon-gamma | 3 | 2020 | 2711 | 0.44 | Why? |
| Antibody Formation | 3 | 2021 | 4038 | 0.43 | Why? |
| Antigens, Protozoan | 4 | 2018 | 121 | 0.42 | Why? |
| Ebolavirus | 1 | 2017 | 834 | 0.41 | Why? |
| Protozoan Proteins | 4 | 2018 | 205 | 0.38 | Why? |
| Epitopes | 2 | 2018 | 4113 | 0.31 | Why? |
| CD4-Positive T-Lymphocytes | 2 | 2020 | 4545 | 0.30 | Why? |
| Hemorrhagic Fever, Ebola | 1 | 2017 | 1475 | 0.30 | Why? |
| Drug Evaluation, Preclinical | 1 | 2017 | 3347 | 0.29 | Why? |
| Vaccination | 7 | 2021 | 19050 | 0.26 | Why? |
| Drug Discovery | 1 | 2017 | 3092 | 0.25 | Why? |
| Liver | 1 | 2018 | 4007 | 0.25 | Why? |
| Adenoviruses, Simian | 2 | 2020 | 52 | 0.24 | Why? |
| Immunity, Cellular | 4 | 2020 | 3614 | 0.23 | Why? |
| Vaccinia | 2 | 2018 | 32 | 0.23 | Why? |
| Protein Subunits | 2 | 2020 | 755 | 0.21 | Why? |
| Immunity, Humoral | 4 | 2020 | 4849 | 0.21 | Why? |
| Immunogenicity, Vaccine | 3 | 2020 | 4624 | 0.20 | Why? |
| Enzyme-Linked Immunospot Assay | 2 | 2017 | 325 | 0.19 | Why? |
| Dose-Response Relationship, Immunologic | 1 | 2020 | 593 | 0.19 | Why? |
| Specimen Handling | 1 | 2017 | 6190 | 0.19 | Why? |
| Interferometry | 1 | 2018 | 74 | 0.19 | Why? |
| Vaccines | 1 | 2017 | 3692 | 0.18 | Why? |
| Flow Cytometry | 2 | 2017 | 2393 | 0.18 | Why? |
| Single-Blind Method | 4 | 2021 | 1283 | 0.16 | Why? |
| Staining and Labeling | 1 | 2017 | 169 | 0.16 | Why? |
| Saponins | 1 | 2017 | 171 | 0.15 | Why? |
| Africa, Western | 1 | 2017 | 363 | 0.15 | Why? |
| Clinical Trials, Phase I as Topic | 1 | 2017 | 242 | 0.15 | Why? |
| Vaccinia virus | 1 | 2018 | 346 | 0.15 | Why? |
| Immunoglobulin Isotypes | 1 | 2017 | 308 | 0.14 | Why? |
| Immunization Schedule | 1 | 2021 | 1305 | 0.13 | Why? |
| Antibody Affinity | 1 | 2018 | 1078 | 0.13 | Why? |
| CD8-Positive T-Lymphocytes | 2 | 2020 | 5837 | 0.12 | Why? |
| Lymphocyte Activation | 1 | 2020 | 2742 | 0.11 | Why? |
| Immunoglobulin A | 1 | 2020 | 3567 | 0.09 | Why? |
| Viral Vaccines | 2 | 2020 | 7560 | 0.09 | Why? |
| Membrane Proteins | 2 | 2017 | 1733 | 0.09 | Why? |
| Adolescent | 10 | 2021 | 86841 | 0.09 | Why? |
| Africa | 1 | 2017 | 2986 | 0.09 | Why? |
| Young Adult | 9 | 2021 | 93724 | 0.08 | Why? |
| Adjuvants, Immunologic | 2 | 2017 | 1709 | 0.08 | Why? |
| Nanoparticles | 1 | 2017 | 2040 | 0.07 | Why? |
| Immunoglobulin M | 1 | 2020 | 9091 | 0.06 | Why? |
| Vaccines, DNA | 2 | 2020 | 871 | 0.06 | Why? |
| Humans | 19 | 2021 | 930598 | 0.06 | Why? |
| Malaria | 1 | 2011 | 1097 | 0.06 | Why? |
| Middle Aged | 11 | 2021 | 270681 | 0.05 | Why? |
| Enzyme-Linked Immunosorbent Assay | 1 | 2017 | 7868 | 0.05 | Why? |
| Europe | 1 | 2017 | 12702 | 0.05 | Why? |
| Female | 11 | 2021 | 380317 | 0.05 | Why? |
| United Kingdom | 4 | 2021 | 18046 | 0.05 | Why? |
| Antibodies, Neutralizing | 3 | 2021 | 25288 | 0.05 | Why? |
| Analgesics, Non-Narcotic | 1 | 2020 | 164 | 0.05 | Why? |
| Adult | 11 | 2021 | 244371 | 0.05 | Why? |
| Male | 10 | 2021 | 367725 | 0.04 | Why? |
| Acetaminophen | 1 | 2020 | 326 | 0.04 | Why? |
| CD4 Lymphocyte Count | 1 | 2021 | 1517 | 0.04 | Why? |
| Spike Glycoprotein, Coronavirus | 3 | 2020 | 37182 | 0.04 | Why? |
| Infant, Newborn | 1 | 2017 | 23105 | 0.04 | Why? |
| HIV Infections | 1 | 2021 | 11620 | 0.04 | Why? |
| Mycobacterium tuberculosis | 1 | 2004 | 1164 | 0.04 | Why? |
| Vaccines, Attenuated | 1 | 2020 | 952 | 0.03 | Why? |
| Animals | 3 | 2020 | 78931 | 0.03 | Why? |
| Infant | 1 | 2017 | 30274 | 0.03 | Why? |
| Child, Preschool | 1 | 2017 | 36283 | 0.03 | Why? |
| Aluminum Hydroxide | 1 | 2011 | 133 | 0.03 | Why? |
| Antibodies, Viral | 2 | 2021 | 51949 | 0.03 | Why? |
| Dose-Response Relationship, Drug | 1 | 2020 | 3776 | 0.03 | Why? |
| Immunoglobulin G | 3 | 2020 | 21571 | 0.03 | Why? |
| Oligodeoxyribonucleotides | 1 | 2011 | 206 | 0.03 | Why? |
| South Africa | 1 | 2020 | 3326 | 0.03 | Why? |
| Double-Blind Method | 1 | 2020 | 5988 | 0.02 | Why? |
| T-Lymphocyte Subsets | 1 | 2017 | 1387 | 0.02 | Why? |
| Tuberculosis | 1 | 2004 | 2895 | 0.02 | Why? |
| Immunization | 1 | 2017 | 2019 | 0.02 | Why? |
| Vaccines, Synthetic | 1 | 2020 | 3231 | 0.02 | Why? |
| Child | 1 | 2017 | 70012 | 0.02 | Why? |
| Nucleic Acid Amplification Techniques | 1 | 2021 | 3388 | 0.02 | Why? |
| Antibodies | 1 | 2011 | 846 | 0.02 | Why? |
| Immunologic Memory | 1 | 2017 | 3362 | 0.02 | Why? |
| Betacoronavirus | 2 | 2020 | 204454 | 0.02 | Why? |
| Brazil | 1 | 2020 | 12582 | 0.02 | Why? |
| Genes, Bacterial | 1 | 2004 | 207 | 0.02 | Why? |
| Asymptomatic Infections | 1 | 2021 | 7218 | 0.01 | Why? |
| Randomized Controlled Trials as Topic | 1 | 2021 | 10649 | 0.01 | Why? |
| Aged | 4 | 2021 | 215776 | 0.01 | Why? |
| Antigens, Bacterial | 1 | 2004 | 330 | 0.01 | Why? |
| Clinical Trials as Topic | 1 | 2020 | 7330 | 0.01 | Why? |
| In Vitro Techniques | 1 | 2004 | 1027 | 0.01 | Why? |
| Viral Load | 1 | 2021 | 15850 | 0.01 | Why? |
| Age Factors | 1 | 2020 | 21039 | 0.01 | Why? |
| Disease Models, Animal | 1 | 2017 | 10998 | 0.01 | Why? |
| Pandemics | 3 | 2021 | 389249 | 0.01 | Why? |
| Molecular Sequence Data | 1 | 2004 | 3198 | 0.01 | Why? |
| Time Factors | 1 | 2020 | 31397 | 0.01 | Why? |
| Mice | 1 | 2017 | 21357 | 0.01 | Why? |
| Bacterial Proteins | 1 | 2004 | 1318 | 0.01 | Why? |
| Pneumonia, Viral | 2 | 2020 | 243684 | 0.01 | Why? |
| Coronavirus Infections | 2 | 2020 | 253789 | 0.01 | Why? |
| Treatment Outcome | 1 | 2020 | 51732 | 0.01 | Why? |
| BCG Vaccine | 1 | 2004 | 1137 | 0.01 | Why? |
| Cross Reactions | 1 | 2004 | 4374 | 0.01 | Why? |
| Amino Acid Sequence | 1 | 2004 | 6049 | 0.01 | Why? |
| Aged, 80 and over | 1 | 2020 | 88759 | 0.01 | Why? |
| Case-Control Studies | 1 | 2004 | 17671 | 0.00 | Why? |
| Sensitivity and Specificity | 1 | 2004 | 22971 | 0.00 | Why? |
| Prospective Studies | 1 | 2004 | 43301 | 0.00 | Why? |
Ewer's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts
(121)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(210)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_